{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:51:46Z","timestamp":1779216706309,"version":"3.51.4"},"reference-count":45,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2019,3,1]]},"abstract":"<jats:p>\n                    The objective of this study was to evaluate the frequency of different extended-spectrum \u03b2-lactamases (ESBL) as well as to associate these ESBL with antimicrobial (ATM) resistance in\n                    <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                    and\n                    <jats:italic toggle=\"yes\">Klebsiella<\/jats:italic>\n                    spp. isolates from outpatients and inpatients with urinary tract infections. The study included 435 consecutive nonduplicate clinical isolates, including 362\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    isolates, 62\n                    <jats:italic toggle=\"yes\">Klebsiella pneumoniae<\/jats:italic>\n                    isolates, and 11\n                    <jats:italic toggle=\"yes\">K. oxytoca<\/jats:italic>\n                    isolates. Isolates were obtained from patients who were treated in a University Hospital between August 2012 and July 2013. Three multiplex PCR were performed to identify the ESBL groups. A total of 48 (11%) ESBL-producing isolates were found. The risk for the ESBL presence was significantly higher in males (26.4%) than females (8%), from hospital-acquired infections (29.1%) than community-acquired infections (7.0%) and in\n                    <jats:italic toggle=\"yes\">Klebsiella<\/jats:italic>\n                    spp. (27.4%) than in\n                    <jats:italic toggle=\"yes\">E. coli<\/jats:italic>\n                    (7.7%). ESBL-producing isolates presented a significantly higher percentage of resistance in 21 of the 23 ATMs analyzed. The CTX-M-1 group was the most predominant ESBL identified. The\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>CTX-M-1-group<\/jats:sub>\n                    gene was found in 56% of the total ESBL producers from community and in 42.4% from hospital origins; it was followed in frequency by the\n                    <jats:italic toggle=\"yes\">bla<\/jats:italic>\n                    <jats:sub>CTX-M-8\/25-group<\/jats:sub>\n                    , also found in both environments.\n                    <jats:italic toggle=\"yes\">Klebsiella<\/jats:italic>\n                    spp. presented the largest variety of \u03b2-lactamase enzyme combinations and a higher level of resistance to cefotaxime. These findings contribute to better knowledge of the epidemiology of ESBL enzymes and are alarming for the reduced therapeutic options available for the risk groups identified in the studied populations.\n                  <\/jats:p>","DOI":"10.1089\/mdr.2018.0046","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T15:25:19Z","timestamp":1534951519000},"page":"173-181","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Antimicrobial Resistance and Molecular Characterization of Extended-Spectrum \u03b2-Lactamases of\n                    <i>Escherichia coli<\/i>\n                    and\n                    <i>Klebsiella<\/i>\n                    spp. Isolates from Urinary Tract Infections in Southern Brazil"],"prefix":"10.1177","volume":"25","author":[{"given":"Juliano Lacava","family":"Pereira","sequence":"first","affiliation":[{"name":"Universidade Federal do Rio Grande\u2014FURG","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisiane Martins","family":"Volc\u00e3o","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande\u2014FURG","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel Baracy","family":"Klafke","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande\u2014FURG","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roseli Stone","family":"Vieira","sequence":"additional","affiliation":[{"name":"Hospital Universit\u00e1rio Dr. Miguel Riet Correa","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla Vitola","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande\u2014FURG","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivy Bastos","family":"Ramis","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande\u2014FURG","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Eduardo Almeida","family":"da Silva","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande\u2014FURG","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"von Groll","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande\u2014FURG","place":["Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00473-0"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2013.09.003"},{"key":"e_1_3_3_4_2","unstructured":"World Health Organization (WHO). 2014. Antimicrobial resistance: global report on surveillance. Available at www.who.int\/drugresistance\/documents\/surveillancereport\/en\/ (accessed September4 2017)."},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.4.657-686.2005"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.933-951.2001"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2014.08.002"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00117-13"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0122"},{"key":"e_1_3_3_10_2","first-page":"1","article-title":"Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective","volume":"4","author":"Brolund A.","year":"2014","unstructured":"Brolund A. 2014. Overview of ESBL-producing Enterobacteriaceae from a Nordic perspective. Infect. Ecol. Epidemiol., 4:1\u20139.","journal-title":"Infect. Ecol. Epidemiol."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv441"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.17511\/ijmrr.2016.i06.24"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq415"},{"key":"e_1_3_3_14_2","first-page":"1301","article-title":"Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. cephalosporins and aztreonam, Clin","volume":"56","author":"Dudley M.N.","year":"2013","unstructured":"Dudley M.N., , Ambrose P.G., , Bhavnani S.M., , Craig W.A., , Ferraro M.J., , Jones R.N., for the Antimicrobial Susceptibility Testing Subcommittee of the Clinical and Laboratory Standards Institute. 2013. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. cephalosporins and aztreonam, Clin. Infect. Dis. 56:1301\u20131309.","journal-title":"Infect. Dis"},{"key":"e_1_3_3_15_2","unstructured":"Ministry of Health Brazil. 1998. Ordinance 2616\/98 of May 12 1998. Regulates the actions to control hospital infection in the country [In Portuguese]. Available at http:\/\/bvsms.saude.gov.br\/bvs\/saudelegis\/gm\/1998\/prt2616_12_05_1998.html (accessed October17 2017)."},{"key":"e_1_3_3_16_2","unstructured":"Clinical and Laboratory Standards Institute Edition. Approved standard\u2014ninth. 2012. CLSI document M07-A9. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.46160-0"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkp498"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2010.11.022"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AEM.02113-06"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.6.1211"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1517-83822013005000038"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2016.02.003"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-015-0095-5"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2395-8"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(00)00168-0"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/518605"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_3_29_2","first-page":"18","article-title":"Factors associated with resistance to ciprofloxacin and levofloxacin in Gram-negative isolates from urinary tract infections","volume":"6","author":"Volc\u00e3o L.M.","year":"2016","unstructured":"Volc\u00e3o L.M., , Pereira J.L., , Ramis I.B., , Ramos D.F., , Damati G.S., , Gon\u00e7alves C.V., , Silva P.E.A., , and Groll A.V.. 2016. Factors associated with resistance to ciprofloxacin and levofloxacin in Gram-negative isolates from urinary tract infections. Rev. Epidemiol. Control. Infec\u00e7\u00e3o., 6:18\u201323.","journal-title":"Rev. Epidemiol. Control. Infec\u00e7\u00e3o."},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.12.013"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(09)70054-4"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01707-08"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2015.0180"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0009-2015"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1413-86702011000500002"},{"key":"e_1_3_3_36_2","first-page":"1970","volume-title":"Antimicrob. Agents Chemother.","author":"Sabat\u00e9 M.R.","year":"2000","unstructured":"Sabat\u00e9 M.R., , Tarrago F., , Navarro E., , Mir\u00f3 E., , Verg\u00e9s C., , Barb\u00e9 J., , and Prats G.. 2000. Cloning and sequence of the gene encoding a novel cefotaxime-hydrolyzing beta-lactamase (CTX-M-9) from Escherichia coli in Spain. Antimicrob. Agents Chemother., 44:1970\u20131973."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.8.2269-2275.2001"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.5897\/AJMR2014.7340"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.7.1936-1942.2000"},{"key":"e_1_3_3_40_2","first-page":"1039","volume-title":"Clin. Microbiol. Infect.","author":"Peirano G.","year":"2011","unstructured":"Peirano G., , Asensi M.D., , Pitondo-Silva A., , and Pitout J.D.D.. 2011. Molecular characteristics of extended-spectrum \u03b2-lactamase-producing Escherichia coli from Rio de Janeiro, Brazil. Clin. Microbiol. Infect., 17:1039\u20131043."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00110"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.3.622-632.2000"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku332"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.180.17.4686-4692.1998"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.181.9.2726-2732.1999"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.10.2777-2783.2000"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2018.0046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2018.0046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:33:13Z","timestamp":1777667593000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2018.0046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,3,1]]}},"alternative-id":["10.1089\/mdr.2018.0046"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2018.0046","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}